These modification techniques include the addition of a chimeric antigen receptor (CAR) to γδ T cells to create CAR-γδ T cells; the transfer of antitumor γδ TCR to αβ T cells (TEG001, GDT002, GDT201); the fusion of an antibody anti-CD19 Fab region and the transmembrane andendo domains of a γδ TCR, as well as a separate CD19 single-chain variable fragment (scFv) and a 4-1BB costimulatory molecule, to create a novel T cell (ET019003) to treat B-cell lymphoma (84). This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.